Pentoxifylline for heart failure: A systematic review

South African Medical Journal

Volumn 95, Issue 3, 2005, Pages 171-175

  Batchelder, Kathryn ^a   Mayosi, Bongani M ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE; PLACEBO;

CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; QUALITY CONTROL; RATING SCALE; REVIEW; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

DOUBLE-BLIND METHOD; HEART FAILURE, CONGESTIVE; HUMANS; PENTOXIFYLLINE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; STROKE VOLUME; TREATMENT OUTCOME; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 16244409000     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Miller LW, Missov ED. Epidemiology of heart failure. Cardiol Clin 2001; 19: 547-555.
2. Mayosi BM, Khogali S, Zhang B, Watkins H. Cardiac and skeletal actin gene mutations are not a common cause of dilated cardiomyopathy. J Med Genet 1999; 36: 796-797.
3. Bleumink GS, Knetscha AM, Sturkenboom MCJM, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure - The Rotterdam Study. Eur Heart J 2004; 25: 1614-1619.
4. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998; 351: 1091-1093.
5. Skudicky D, Sliwa K, Bergemann A, Candy G, Sareli P. Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline. Heart 2000; 84: 438-441.
6. Skudicky D, Bergemann A, Sliwa K, Candy G, Sareli P. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol. Circulation 2001; 103: 1083-1088.
7. Sliwa K, Woodiwiss A, Candy G, et al. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 2002; 90: 1118-1122.
8. Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. European Journal of Heart Failure 2002; 4: 305-309.
9. Sliwa K, Woodiwiss A, Kone VN, et al. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomised study. Circulation 2004; 109: 750-755.
10. Rauchhaus M, Droehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102: 3060-3067.
11. Suresh R, Vig M, Bhatia S, et al. Pentoxifylline functions as an adjunct in vivo to enhance T cell immune response by inhibiting activation-induced death. J Immunol 2002; 169: 4262-4272.
12. Review Manager. Computer program version 4.1. Oxford: Update Software, 2001.
13. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-613.